UK Markets open in 5 hrs 52 mins

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
28.60+0.06 (+0.21%)
At close: 04:00PM EDT
28.60 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.49
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 356.30
52-week low 319.85
50-day moving average 331.56
200-day moving average 331.00

Share statistics

Avg vol (3-month) 3574.4k
Avg vol (10-day) 3496.95k
Shares outstanding 546.66M
Implied shares outstanding 6N/A
Float 841.2M
% held by insiders 10.21%
% held by institutions 1109.23%
Shares short (14 Jul 2022) 43.81M
Short ratio (14 Jul 2022) 42.93
Short % of float (14 Jul 2022) 49.61%
Short % of shares outstanding (14 Jul 2022) 48.15%
Shares short (prior month 14 Jun 2022) 44.71M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 310 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 310 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,854.71%

Management effectiveness

Return on assets (ttm)-14.93%
Return on equity (ttm)-26.01%

Income statement

Revenue (ttm)4.14M
Revenue per share (ttm)0.09
Quarterly revenue growth (yoy)-74.60%
Gross profit (ttm)-48.66M
EBITDA -73.68M
Net income avi to common (ttm)-77.02M
Diluted EPS (ttm)-2.02
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)380.47M
Total cash per share (mrq)8.14
Total debt (mrq)2.64M
Total debt/equity (mrq)0.66
Current ratio (mrq)26.83
Book value per share (mrq)5.29

Cash flow statement

Operating cash flow (ttm)-67.36M
Levered free cash flow (ttm)-42.97M